Researchers at the University of Pittsburgh have developed fully human monoclonal antibodies (mAbs) targeting the acetylhydrolase PLA2G7, which is secreted by macrophages and interacts with oxidized low-density lipoprotein (oxLDL). These antibodies have shown potential in blocking PLA2G7-mediated inflammation and macrophage activation, offering novel therapeutic avenues for anti-aging and cancer treatment. The antibodies were identified through panning of phage-displayed Fab and VH libraries, and have demonstrated high specificity and efficacy in blocking PLA2G7 enzymatic activity and cell migration.
Description
PLA2G7, also known as platelet-activating factor acetylhydrolase (PAF-AH), hydrolyzes oxLDL into lysophosphatidylcholine (lysoPC) and oxidized non-esterified fatty acids (oxNEFAs), leading to inflammation in blood vessels. Elevated PLA2G7 levels are associated with various vascular diseases and cancers. The developed mAbs, including 1H8 Fab, 1A9 VH, and their bispecific formats, have shown high specificity to PLA2G7 and effectively block its enzymatic activity. These antibodies represent the first fully human immune blockade of PLA2G7, with potential applications in anti-tumor and anti-aging therapies.
Applications
• Therapeutic antibody
• Cancer therapy
• Inflammatory disorders
• Cardiovascular diseases
Advantages
• High specificity and affinity to PLA2G7
• Effective blockade of PLA2G7 enzymatic activity
• Potential to reduce macrophage activation and chronic inflammation
• Novel therapeutic approach for anti-aging and cancer treatment
Invention Readiness
The antibodies have been developed
and tested in vitro, demonstrating high specificity and efficacy
in blocking PLA2G7 activity and cell migration. The next steps include further preclinical and clinical evaluations to establish their therapeutic potential.
IP Status
Patent Pending
